Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2025Cardiology in Review

Semaglutide significantly reduced the overall incidence of cardiovascular mortality compared with placebo in obese patients with heart failure (RR 0.74; 95% CI 0.58-0.94; P=0.02).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Semaglutide improves cardiovascular outcomes in obese patients, but its role in patients with heart failure remained unclear.

Does semaglutide reduce cardiovascular mortality in obese patients with heart failure?

Population

6898 obese heart failure patients regardless of baseline ejection fraction across 5 RCTs

Comparison

Semaglutide vs placebo

Design

Meta-analysis of randomized controlled trials

Key result

Semaglutide significantly reduced the overall incidence of cardiovascular mortality compared with placebo in obese patients with heart failure (RR 0.74; 95% CI 0.58-0.94; P=0.02).

Authors

ZOZina OtmaniMYMazen Negmeldin Aly YassinMSM. Saihi

Discussion

Loading...

Member takes

Overview

Semaglutide may lower CV mortality and improve symptoms in obese HF; extends RCT data but requires dedicated long-term trials.

Study Design

Type

Meta-Analysis (n=6,898)

Structured PICO

Does semaglutide reduce cardiovascular mortality in obese patients with heart failure?

P
Population
6,898 obese patients with heart failure regardless of baseline ejection fraction included from 5 randomized controlled trials.
I
Intervention
Semaglutide
C
Comparator
Placebo
O
Outcome
Incidence of cardiovascular (CV) mortalityhard clinical

Main Result

Relative Risk: 0.74 (95% CI 0.58–0.94)

p-value: p=0.02

In a meta-analysis of obese patients with heart failure, semaglutide significantly reduced cardiovascular mortality and improved symptoms and physical function compared to placebo.

Limitations

  • Lack of long-term RCT data

Cite This Study

Otmani et al. (2025) conducted a meta-analysis in Obesity and Heart Failure (n=6,898). Semaglutide vs. Placebo was evaluated on Incidence of cardiovascular (CV) mortality (RR 0.74, 95% CI 0.58-0.94, p=0.02). Semaglutide significantly reduced the overall incidence of cardiovascular mortality compared with placebo in obese patients with heart failure (RR 0.74; 95% CI 0.58-0.94; P=0.02).

synapsesocial.com/papers/6a9773d590d51c6c12fac2a5https://doi.org/10.1097/crd.0000000000000925
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial2016 · 585 citations
  2. 2Quality of Life in Heart Failure with Preserved Ejection Fraction: Importance of Obesity, Functional Capacity, and Physical Inactivity2020 · 241 citations
  3. 3Heart failure with preserved ejection fraction: New approaches to diagnosis and management2019 · 144 citations
  4. 4Relationships between Obesity, Cardiorespiratory Fitness, and Cardiovascular Function2010 · 50 citations
  5. 5Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity2023 · 1,608 citations